Preparat: Efastad, Efexor, Efexor Depot, Efexor®, Efexor® Depot, Vandral Depot, Venlafaxin 1A Farma, Venlafaxin 2care4, Venlafaxin Actavis, Venlafaxin Arrow, Venlafaxin Depot Paranova, Venlafaxin Ebb, Venlafaxin EQL Pharma, Venlafaxin Hexal, Venlafaxin Krka, Venlafaxin Liconsa, Venlafaxin Medical Valley, Venlafaxin Mylan, Venlafaxin Orifarm, Venlafaxin Orion, Venlafaxin Ranbaxy, Venlafaxin ratiopharm, Venlafaxin Sandoz, Venlafaxin STADA, Venlafaxine Bluefish, Venlatab
ATC kod: N06AX16
Substanser: venlafaxin, venlafaxinhydroklorid
Inga kliniskt viktiga könsrelaterade skillnader i effekt av venlafaxin har observerats. Varierande resultat gällande farmakokinetiska skillnader för venlafaxin mellan kvinnor och män finns rapporterat. Till exempel har observationella koncetrationsstudier visat att kvinnor hade högre dosjusterade venlafaxin-koncentrationer.
Kunskapsunderlaget avseende skillnader mellan kvinnor och män är begränsat och motiverar inte olika dosering eller behandling.
In a pharmacokinetic study where patients (18 men, 18 women) first received a single dose 50 mg venlafaxine and later a 50 mg dose every 8 hours for 5 days, only minimal sex differences were observed. After the single dose, women had higher Cmax and AUC of the metabolite O-desmetylvenlafaxine (ODV), while men had longer ODV Tmax. When multiple dosing, women had faster venlafaxine renal clearance and men had longer ODV half-life . In another pharmacokinetic study (14 men, 21 women) with 300mg/day, women showed a reduced ODV/venlafaxine ratio for the (-)-enantiomer of ODV after 14 days but no sex differences were observed for the (+)-enantiomer. Similar results were seen after 28 days . Several therapeutic drug monitoring studies (in all 732 men, 1259 women) have shown that women had higher concentrations of venlafaxin and its metabolites [3-5]. According to the manufacturer, no sex differences in the pharmacokinetics of venlafaxine and its metabolite ODV are expected and no sex differentiation in dosing are recommended . Published pharmacokinetic studies support similar dosing in men and women [1, 2].
Men and women with major depressive disorders have shown similar treatment response of venlafaxine in randomized, double-blind, controlled trials (in all 1058 men, 2059 women) [7, 8]. Treatment response of venlafaxine was also examined in patients with posttraumatic stress disorder in a pooled analysis (271 men, 416 women), but no significant sex differences were observed .
Isolated cases of Torsade de pointes ventricular tachycardia have been reported in association with venlafaxine overdose, the risk is generally higher in women .
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
A small British study (48 men, 46 women) examining the choice of antidepressant treatment in relation to suicide risk showed that less venlafaxine was prescribed to men than women. Patients received monotherapy treatment for depression of which 6 men and 19 women were treated with venlafaxine .
Prescription history during the first year after the introduction of mirtazapine, sertraline and venlafaxine has been collected from 20 pharmacies in the Netherlands. No sex differences in distribution were observed . However, male sex has been associated with a greater risk of treatment drop-out than women, reports a Spanish study based on prescription data. Patients who had received at least one antidepressant drug were included (in all 7525 patients) .
Fler kvinnor än män hämtade ut tabletter/kapslar innehållande venlafaxin (ATC-kod N06AX16) på recept i Sverige år 2015, totalt 54 231 kvinnor och 31 653 män. Det motsvarar 11 respektive 7 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 35-64 år hos båda könen. I genomsnitt var tabletter/kapslar innehållande venlafaxin 1,7 gånger vanligare hos kvinnor .
Faktagranskat av: Expertrådet för psykiatriska sjukdomar, Expertrådet för geriatriska sjukdomar, Mia von Euler
Godkänt av: Karin Schenck-Gustafsson